Æâ²Ê³ØÂè»°¹ÖºÂ

¡Ô¸¦µæ¶ÈÀÓ¡Õ


¸¶¡¡¡¡Ãø

  1. ÆâÅÄÍΰìϯ, Ë̽йÀ¾Ï¡¤³¤ËÙ¾»¼ù¡¤Àî¸ýͺºÍ¡¤ÜÞ¡¡²í·û¡¤¾¾²¼¶©¹§¡¤ºä°æÅĵª»Ò¡¤¾å»³¡¡ÂÙÃË (2001)
    ¾å¹Ô·ëIJ·Æ¼¼±ê¤Ëcolonic muco-submucosal elongated polyp¤ò¹çÊ»¤·¤¿£±Îã.
    ÆüÎ׳°³Ø»ï 62:446¡Á450
  2. Fujii T, Seki T, Maruoka M, Tanaka J, Kawashima Y, Watanabe T, Sawamura T and Inoue K (2001)
    Lactulose-L-rhamnose intestinal permeability test in patients with liver cirrhosis.
    Hepatol Res 19:158¡Á169
  3. Kato T, Tamura S, A Tekin, Yamashiki N, Seki T, M Berho, D Weppler, Izumi N, D Levi, F Khan, A Pinna, J Nery and A.G Tzakis (2001)
    Use of microwave coagulation therapy in liver transplant candidates with hepatocellular carcinoma: A preliminary report.
    Transplantation Proceedings 33:1469
  4. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, Nakagawa T and Inoue K (2001)
    Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumor region.
    Eur J Gastroenterol Hepatol 13:291¡Á294
  5. Takaoka M, Kubota Y, Tsuji K, Yamamoto S, Ogura M, Yanagitani K, Shimatani M, Shibatani N and Inoue K (2001)
    Human neutrophil functions in obstructive jaundice.
    Hepato-Gastroenterology 48:71¡Á75
  6. À§»Þ¤Á¤Å, ¿åÌî¹§»Ò¡¤°æ¾å¶³°ì¡¤²Ï¡¡ÁêµÈ (2001)
    Áíʬ´ôº¿¥¢¥ß¥Î»À/¥Á¥í¥·¥ó¥â¥ëÈæ(BTR)¤Î´ÎͽÈ÷ǽ¿ÇÃÇË¡¤È¤·¤Æ¤Îɾ²Á¡Ý¥¢¥·¥¢¥í¥·¥ó¥Á¤È¤Î´ØÏ¢¡Ý.
    ÌôÍý¤È¼£ÎÅ 29(Suppl.1) : S65¡ÁS71
  7. »³ËÜÃÒ¼÷»Ò,ÃÝËÜÍο͡¤µ×Ìî·òÆó¡¤À¾Â¼¡¡¾Ï¡¤¶Ì°æ¡¡Å°¡¤º£Â¼Àµ¿Í¡¤ÃæÀîÂٰ졤À§»Þ¤Á¤Å¡¤´Ø¡¡¼÷¿Í¡¤°æ¾å¶³°ì¡¤ÇÅËá·É»°¡¤¾å»³ÂÙÃË(2001)
    ¥Þ¥¤¥¯¥í¥»¥ì¥¯¥È¥í¥óHDR192Ir¤òÍѤ¤¤¿Êü¼ÍÀþÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÌçÌ®¼ðáçÀò¹çÊ»´ÎºÙ˦´â¤Î£±Îã.
    ´Î¡ 42:373¡Á377
  8. »³ËÜÂç¸ç, ÅÄÃæ´°»ù¡¤Ãæ°æ¹¨¼£¡¤ÇÏÅÂŰÌ顤ÆüÃֹɻÎϺ¡¤»³ËÜÃÒ¼÷»Ò¡¤°æ¾å¶³°ì(2001)
    Cycloprodigiosin hydrochloride (cPrG¡¦HCl; H+Cl- symporter)¤È±ö»À¥¨¥Ô¥ë¥Ó¥·¥ó¤ÎÊ»ÍѸú²Ì¤Èµ¡¹½¤Î²òÀÏ.
    Æý´â´ðÁø¦ 10:52¡Á55
  9. Yamamoto C, Takemoto H, Kuno K, Yamamoto D, Nakai K, Baden T, Kamata K, Hirata H, Watanabe T and Inoue K (2001)
    Cycloprodigiosin hydrochloride, a H+/Cl- symporter, induces apoptosis in human colon cancer cell lines in vitro.
    Oncology Reports 8:821¡Á824
  10. °æ¾å¶³°ì (2001)
    ¸üÀ¸²Ê³Ø¸¦µæÈñÊä½õ¶â¡ÊÆÃÄê¼À´µÂкö¸¦µæ»ö¶È¡ËÁí³ç¸¦µæÊó¹ð½ñ¡§¸¶È¯À­ÃÀ½ÁÀ­´Î¹ÅÊѸ¦µæÊ¬²Ê²ñÁí³çÊó¹ð½ñ
    ¸üÀ¸Ï«Æ¯¾Ê´Î±ê¸¦µæÏ¢Íí¶¨µÄ²ñ¡¡Ê¿À®12ǯÅÙ¸¦µæÊó¹ð 29
  11. Tahashi Y, Matsuzaki K, Date M, Furukawa F, Sugano Y, Matsushita M, Inagaki Y and Inoue K (2001)
    Differential regulation of autocrine transforming growth factor beta signal in hepatic stellate cells between acute and chronic rat liver injury: Implications regarding the role of Smads in liver fibrosis.
    Hepatology in press
  12. Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M and Toda G (2001)
    Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC) .
    Hepatol Res 22:250-260

Áí¡¡¡¡Àâ

  1. ¾¾ºê¹±°ì, ÅͶ¸­Ì顤°æ¾å¶³°ì (2001)
    ÆÃ½¸¡É´ÎÀþ°Ý²½¤ÈÉÂÂÖ¡É´ÎÀþ°Ý²½¤ÈTGF-¦Â¥·¥°¥Ê¥ëÅÁ㵡¹½.
    BIO Clin 16:304¡Á309
  2. ´Ø ¼÷¿Í, °æ¾å¡¡¶³°ì (2001)
    ÆÃ½¸"´ÎºÙ˦´â¤Î¤¹¤Ù¤Æ¡É´ÎºÙ˦´â¤Î¼£ÎÅ¡ÝŬ±þ¡¤¼êË¡¡¤À®ÀÓ¡Ý ·ÐÈéŪ¥Þ¥¤¥¯¥íÇȶŸǼ£ÎÅ.
    ¾Ã³° 24:694¡Á699
  3. ¶Ì°æ¡¡Å°, ´Ø¡¡¼÷¿Í¡¤°æ¾å¶³°ì (2001)
    ÆÃ½¸¡É¿ÊÊ⤷¤¿´Î¤¬¤ó¤ÎÁá´üȯ¸«¤È¼£Îšɼ£ÎÅË¡¤ÎÁªÂò¡Ý²½³ØÎÅË¡.
    Îפȸ¦¡¡ 78:1245¡Á1248
  4. ¹â¿Ü²í»Ë, ÉðÅÄÀ»»Ò¡¤°æ¾å¶³°ì (2001)
    ÆÃ½¸¡É´Î±ê¡ÝºÇ¿·¤Î¼£ÎÅË¡¤ËÇ÷¤ë¡Ý¡É¥¢¥ë¥³¡¼¥ë¡¦ÌôºÞÀ­´Î¾ã³²¤Î¿ÇÃǤȼ£ÎÅ.
    º£·î¤Î¼£ÎÅ 9:997¡Á1003
  5. ´Ø¡¡¼÷¿Í, °æ¾å¶³°ì (2001)
    ÆÃ½¸¡É´Î´â¤Î¿ÇÃÇ¡¦¼£ÎŤκÇÁ°Àþ¡É·ÐÈé۶ɽêÎÅË¡¡¡¡Ý¥Þ¥¤¥¯¥íÇȶŸÇÎÅË¡.
    Æâ²Ê¡¡88:680¡Á684
  6. ¡¡¡¡

  7. ¾¾ºê¹±°ì, ¸ÅÀîÉÙµª»Ò (2001)
    ÆÃ½¸¡É¥Ò¥È´ÎºÙ˦¤òÍøÍѤ·¤¿¸¦µæ¤È¤½¤ÎÎ×¾²±þÍѡɴÎÀþ°Ý²½¤ÎÉÂÂÖ¤ÎÇİ®¤È¼£ÎŤؤΟ˾.
    ºÙ˦ 33:422¡Á423
  8. ÃçÌî½ÓÀ®, °æ¾å¶³°ì (2001) ²èÁü¤ò¿Ç¤ë(17)¡Ý´ÕÊÌ¿ÇÃǤΥݥ¤¥ó¥È¡¡¿©Æ»¾®ºÙ˦´â.
    ¾Ã²½´ï¤ÎÎ× 4:396¡Á398
  9. ´Ø¡¡¼÷¿Í (2001)
    ¡É´Î´â¤Î¿ÇÃǤȼ£Îšݺǿ·¤Î¸¦µæÆ°¸þ¡Ý¡É­»¡¥´Î´â¤Î¼£ÎÅ¡¡·ÐÈéŪ¥Þ¥¤¥¯¥íÇȶŸÇÎÅË¡(PMCT)
    ÆüÎ× 59(Áý´©¹æ6):581¡Á585
  10. ¡¡¡¡

  11. ×¢¸¶½ß»Ò, µÜºê¹À¾´¡¤°æ¾å¶³°ì (2001)
    ËýÀ­´Î¼À´µ¤Î¿ÇÃǤȼ£ÎŤκÇÁ°Àþ­¥¡¡¸¶È¯À­ÃÀ½ÁÀ­´Î¹ÅÊÑ Æü°å»Õ²ñ»ï 126:MK-17¡Á20
  12. ¡¡¡¡

  13. ´Ø¡¡¼÷¿Í (2001)
    ÆÃ½¸¡ÉÁá´ü´ÎºÙ˦´â¤Î¼£ÎŤÈͽ¸å¡ÉÁá´ü´ÎºÙ˦´â¤Î¼£ÎÅ¡Ý ¡¡¡¡PMCT¤ÎÀ®ÀÓ.
    ¥¯¥ê¥Ë¥« 28:353¡Á356

³Ø²ñȯɽ

  1. ³¤Æ»Íø¼Â, µÈÀî¡¡ÌÀ¡¤Âç¹¾½¨ÌÀ¡¤²¬Åç¡¡°¦¡¤º£Â¼ÀµÇ· (2001)
    HGF³èÀ­²½µ¡¹½¤«¤é¸«¤¿¹ÅÊÑ´ÎÀÚ½ü¸åºÆÀ¸ÉÔÎɵ¡½ø¤Î²òÌÀ.
    Âè101²óÆüËܳ°²Ê³Ø²ñÁí²ñ, ÀçÂæ
  2. Takamatsu S, Ito S, Oshita M, Katayama K, Kaneko A, Kioka K, Takasu M, Naitoh Y, Nagamatsu R, Nakamura T and Habu Y, Fukuda A, Hongo Y (2001)
    Validation of the SF-36 in patients with chronic liver disease.
    Pan-Pacific Conference of the International Society for Quality of Life Research (ISOQOL), Tokyo
  3. ×¢¸¶½ß»Ò, ÃçÌî½ÓÀ®¡¤°æ¾å¶³°ì (2001)
    ¥·¥ó¥Ý¥¸¥¦¥à(5) ¡É´Î°Ü¿¢¤ÎŬ±þ´ð½à¤ÎºÆÉ¾²Á¡É»ØÄê¡¡¸¶È¯À­ÃÀ½ÁÀ­´Î¹ÅÊÑ(PBC)Á´¹ñÄ´ºº¤Ë¤è¤ë´Î°Ü¿¢Å¬±þ´ð½à¤ÎºÆÉ¾²Á.
    Âè87²óÆüËܾò½´ïɳزñÁí²ñ,¡¡Åìµþ
  4. ¹â²¬¡¡Î¼, µ×ÊÝÅIJ»̡¤»³ËÜ¡¡¿­¡¤ÄÔ¡¡ÏÂÇ·¡¤Åçë¾»ÌÀ¡¤¼ÆÃ«¿­¹Ô¡¤º£°æµÁ¿Î¡¤¾®ÁÒ¿¿Èþ¡¤¿åÌî¹§»Ò¡¤°æ¾å¶³°ì (2001)
    ÃÀƻ»½ý¤Ë¤è¤ëÎÉÀ­ÃÀÆ»¶¹ºõ¤ËÂФ¹¤ëÆâ»ë¶ÀŪ¼£ÎŤθ¡Æ¤.
    Âè61²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñÁí²ñ,¡¡¿À¸Í
  5. ÅͶ¸­Ìé, ¾¾ºê¹±°ì¡¤¸ÅÀîÉÙµª»Ò¡¤¿ûÌî¡¡¹¯¡¤¿¹¡¡ÌÐÀ¸¡¤»³åѱÑÀ¸¡¤µÈÅľ¡µª¡¤¾¾²¼¶©¹§¡¤°æ¾å¶³°ì (2001)
    ¥ï¡¼¥¯¥·¥ç¥Ã¥×19¡É´ÎÀþ°Ý²½¤Î¥á¥«¥Ë¥º¥à¤È¤½¤ÎÀ©¸æ¡É³èÀ­²½À±ºÙ˦¤ª¤è¤Ó·Á¼Áž´¹¤·¤¿¶ÚÀþ°Ý²êºÙ˦¤Ë¤ª¤±¤ëTGF-¦Â¥·¥°¥Ê¥ëÅÁ㵡¹½¤Î¸¡Æ¤¡ÊÂ裱Êó¡Ë.
    Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  6. ³¤Æ»Íø¼Â, µÈÀî¡¡ÌÀ¡¤Âç¹¾½¨ÌÀ¡¤²¬Åç¡¡°¦¡¤°æ¾å¶³°ì¡¤º£Â¼ÀµÇ· (2001)
    ¥ï¡¼¥¯¥·¥ç¥Ã¥×21¡É´ÎÉÔÁ´¤ÎÉÂÂ֤ȼ£ÎÅ¡ÉHGF³èÀ­²½µ¡¹½¤«¤é¸«¤¿¹ÅÊÑ´ÎÀÚ½ü¸å´ÎºÆÀ¸ÉÔÎɵ¡½ø¤Î²òÌÀ.
    Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  7. ËÌÌîµ®¹°, °æ¾å¶³°ì¡¤´Ø¡¡¼÷¿Í¡¤¶Ì°æ¡¡Å°¡¤ÃÓÅĹ̤¡¤À¾Â¼¡¡¾Ï¡¤»³ÉßÀëÂå (2001)
    ¡¡¡¡¥ï¡¼¥¯¥·¥ç¥Ã¥×21¡É´ÎÉÔÁ´¤ÎÉÂÂ֤ȼ£Îšɥ¢¥ó¥â¥Ë¥¢¿À·ÐÆÇÀ­¤ÈNMDA¼õÍÆÂÎ¥µ¥Ö¥¿¥¤¥×¤Î´Ø·¸¤Ë¤Ä¤¤¤Æ
    .¡¡Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  8. ÃçÌî½ÓÀ®, °æ¾å¶³°ì¡¤×¢¸¶½ß»Ò¡¤Èõ¸ýÀ¶Ç¾®ËóÀ¯ÃË¡¤Á¬Ã«´´ÃË¡¤¸ÍÅĹäÂÀϺ (2001)
    ¥ï¡¼¥¯¥·¥ç¥Ã¥×22¡ÉPBC¤ÎÉÂÂ֤ȼ£ÎšɯüËܤˤª¤±¤ë¸¶È¯À­ÃÀ½ÁÀ­´Î¹ÅÊÑ(PBC)¤ÎĹ´üͽ¸å¤Î¿ä°Ü¤È¡¤Ìµ¾É¸õÀ­PBC (a-PBC)¤Ë¤ª¤±¤ëÉ´ü¿ÊŸ¤ÎÍ×°øÊ¬ÀÏ.¡¡
    Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  9. ²¬Åç¡¡°¦, ÆâƣͺÆó¡¤ÌøÃ«¿®¸ã¡¤°æ¾å¶³°ì¡¤³¤Æ»Íø¼Â¡¤µÈÀî¡¡ÌÀ¡¤Âç¹¾½¨ÌÀ¡¤°ËÆ£¹À»Ë¡¤ÊÒ²¬´²¾Ï (2001)
    ¼ï¡¹¤Î´Î¾ã³²¥â¥Ç¥ë¤Ë¤ª¤±¤ëHGFactivator-inhibitor¤Îȯ¸½.
    Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  10. ¾¾ºê¹±°ì, ¸ÅÀîÉÙµª»Ò¡¤ÅͶ¸­Ì顤¿ûÌî¡¡¹¯¡¤¿¹¡¡ÌÐÀ¸¡¤»³åѱÑÀ¸¡¤µÈÅľ¡µª¡¤¾¾²¼¶©¹§¡¤°æ¾å¶³°ì (2001)
    ³èÀ­²½À±ºÙ˦¤ª¤è¤Ó·Á¼Áž´¹¤·¤¿¶ÚÀþ°Ý²êºÙ˦¤Ë¤ª¤±¤ëTGF-¦Â¥·¥°¥Ê¥ëÅÁ㵡¹½¤Î¸¡Æ¤.
    Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  11. À§»Þ¤Á¤Å, º´Æ£ÀµÇ¿åÌî¹§»Ò¡¤°æ¾å¶³°ì¡¤²Ï¡¡ÁêµÈ (2001)
    ËýÀ­´Î¼À´µ¤Ë¤ª¤±¤ëÌÖÆâ·Ïµ¡Ç½¥·¥ó¥Á¤Îɾ²Á¡Ý´ÎÎàÆ¶ÊɺÙ˦µ¡Ç½¤ª¤è¤Ó¥¢¥·¥¢¥í¥·¥ó¥Á¡¤ICG¤È¤ÎÈæ³Ó¡Ý.
    Âè37²óÆüËܴΡ³Ø²ñÁí²ñ,¡¡²£ÉÍ
  12. Matsuzaki¡¡K and Inoue K (2001)
    Differential regulation of autocrine transforming growth factor beta signal in hepatic stellate cells between acute and chronic rat liver injury:Implications regarding the role of Smads in liver fibrosis.
    International Conference on New Strategies for the Treatment of Liver Cirrhosis, at the 33rd Annual Meeting of the Japanese Society for Connective Tissue Research, Tokyo
  13. ¹â²¬¡¡Î¼, µ×ÊÝÅIJ»̡¤»³ËÜ¡¡¿­¡¤ÄÔ¡¡ÏÂÇ·¡¤Åçë¾»ÌÀ¡¤¼ÆÃ«¿­¹Ô¡¤º£°æµÁ¿Î¡¤¹â¸æÆ² ¾Í°ìϺ¡¤¾®ÁÒ¿¿Èþ¡¤¿åÌî¹§»Ò¡¤°æ¾å¶³°ì (2001)
    ÃÀƻ»½ý¤Ë¤è¤ëÃÀ½Áϳ¤ËÂФ¹¤ëÆâ»ë¶ÀŪ¼£ÎŤθ¡Æ¤.
    Âè62²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñÁí²ñ, µþÅÔ
  14. »³ËÜ¡¡¿­, ÃÓ±º¡¡»Ê¡¤Ê¡Å翵ÂÀϺ¡¤Æþ¹¾µ®Íº¡¤ÅͶ¸­Ì顤ŷ±©¹¯Íº¡¤ÃÝÆâ¹¬½Ó¡¤ÃçÌî½ÓÀ®¡¤²ÏÅç¾Íɧ¡¤ÅÏÊÕÉÒɧ¡¤µ×ÊÝÅIJ»̡¤¿åÌî¹§»Ò¡¤°æ¾å¶³°ì (2001)
    Æâ»ë¶ÀŪ°ßÇ´ËìÀÚ½ü¸å¤ÎÎÉÀ­Î´µ¯¤Ë¤Ä¤¤¤Æ¤Î¸¡Æ¤.
    Âè62²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñÁí²ñ, µþÅÔ
  15. º£°æµÁ¿Î, µ×ÊÝÅIJ»̡¤¹â²¬¡¡Î¼¡¤»³ËÜ¡¡¿­¡¤ÄÔ¡¡ÏÂÇ·¡¤Åçë¾»ÌÀ¡¤¼ÆÃ«¿­¹Ô¡¤¹â¸æÆ² ¾Í°ìϺ¡¤¾®ÁÒ¿¿Èþ¡¤¿åÌî¹§»Ò¡¤°æ¾å¶³°ì (2001)
    ERCP¸å¤Î·ìÀ¶¥¢¥ß¥é¡¼¥¼Ãͤ˵ڤܤ¹ç¹´É¥É¥ì¥Ê¡¼¥¸¤Î±Æ¶Á.
    Âè62²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñÁí²ñ, µþÅÔ
  16. ¡¡¡¡

  17. µ×ÊÝÅÄ²Â»Ì (2001)
    ¥µ¥Æ¥é¥¤¥È¥·¥ó¥Ý¥¸¥¦¥à£¶¡ÉÃÀç¹Æâ»ë¶À¼£ÎŤΥ¹¥¿¥ó¥À¡¼¥É²½¤òÌܻؤ·¤Æ¡ÝÃÀÆ»Îΰè¤Ë¤ª¤±¤ë¥Æ¥¯¥Ë¥Ã¥¯¤òÃæ¿´¤Ë¡ÝÆóÉô¡Ý»ä¤Ï¤³¤¦¹Í¤¨¤ë¡Ý¡¡¡ÉÃÀ´É¥¹¥Æ¥ó¥Æ¥£¥ó¥°¡Ý´ðËܼ굻¤È¥¹¥Æ¥ó¥ÈÁªÂò¡Ý.
    DDW-Japan 2001 ¥µ¥Æ¥é¥¤¥È¥·¥ó¥Ý¥¸¥¦¥à, µþÅÔ
  18. Sugano Y, Matsuzaki K, Tahashi Y, Furukawa F, Mori S, Yamagata H, Yoshida K,Matsushita M and Inoue K (2001)
    Distortion of autocrine TGF-¦Â signal accelerates ¡¡¡¡malignant potential by enhancing cell growth as well as PAI-1 and VEGF productions in cultured human hepatocellular carcinoma cells.
    52nd Annual Meeting and Postgraduate Course, the American Association for the Study of Liver Diseases, Dallas
  19. ¡¡¡¡

  20. Matsuzaki K, Furukawa F, Mori S, Tahashi Y, Yoshida K, Yamagata H, Sugano y,Matsushita M and Inoue K (2001)
    Smad 2 activated by autocrine TGF-¦Â signal Merges with MAPK dependent Smad 3 and Smad 4 complex in the nuclei of rat myofibroblasts during chronic liver injury.
    52nd Annual Meeting and Postgraduate Course, the American Association for the Study of Liver Diseases. Dallas
  21. ÃçÌî½ÓÀ®, ÃæÀîÂٰ졤ÅÚÅĹ⹨¡¤°Ë¼¼Í´²ð¡¤Ãç¼ÌÀÈþ¡¤°æ¾åͳÈþ¡¤ÄḫͳÈþ»Ò¡¤Ã§½¨Ï¡¤À¾Ìîŵ¹¨¡¤ÉÙÅÄ¡¡ÌÀ¡¤ÅÄÃæÀ¯Ç»³ËÜÏÂɧ¡¤ÎëÌÚ·òɧ¡¤¹â¶¶ÇìÉס¤°æ¾å¶³°ì¡¤º´Æ£¸øÉ§¡¤Ê¿ÎÉÉðÇ·¡¤º£°æÎÉÊå (2001)
    ³°Íè¾ðÊóɽ¼¨¥·¥¹¥Æ¥à¤Ë¤è¤ë³°Íè¿ÇΞõ¶·¤Î²òÀϤÈɾ²Á.
    Âè21²ó°åΞðÊó³ØÏ¢¹çÂç²ñ¡ÊÂè2²óÆüËܰåΞðÊ󳨲ñ³Ø½ÑÂç²ñ¡Ë, Åìµþ

Ãø¡¡¡¡½ñ

  1. ´Ø¡¡¼÷¿Í (2001)
    ´Î´â¤Î¶É½êÎÅË¡¡Ý¥Þ¥¤¥¯¥íÇȶŸǼ£ÎÅ.
    Àèü°åÎÅ¥·¥ê¡¼¥º ¡¡¡¡11¡¦¾Ã²½´ï¼À´µ¡¡¾Ã²½´ï¼À´µ¤ÎºÇ¿·°åÎÅ 247¡Á252
  2. ¹â¿Ü²í»Ë, °æ¾å¶³°ì (2001)
    ËýÀ­´Î±ê´µ¼Ô¤ÎÀ¸³è»ØÆ³¾å¤ÎÃí°Õ.
    ËýÀ­´Î±ê¿ÇÎÅ ¡¡¡¡¥Þ¥Ë¥å¥¢¥ë 101¡Á107
  3. ¡¡¡¡

  4. °æ¾å¶³°ì, ×¢¸¶½ß»Ò¡¤¹â¿Ü²í»Ë (2001)
    ¼«¸ÊÌȱÖÀ­¼À´µ¤Î¼£ÎÅ¡ÝAIH¡¤PBC¤Ê¤É¤Î¼£ÎŤμºݤȺ£¸å¡Ý.
    ËýÀ­´Î±ê¡ÝºÇ¿·¤Î¼£ÎÅ 205¡Á217

Ê¿À®13ǯ¶ÈÀÓÌÜÏ¿°ìÍ÷¤ËÌá¤ë